BioFocus DPI, Lilly Expand Hormone Receptor Discovery Agreement 
 
Galapagos announced this week that its service division BioFocus DPI has extended its drug discovery agreement with Eli Lilly until the end of 2008.
 
Under the terms of the agreement, BioFocus DPI will screen certain compounds as provided by Lilly against certain selected assays in quarterly screening campaigns to identify active compounds and provide selectivity information for Lilly’s nuclear hormone receptor research program.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.